Read by QxMD icon Read


Hady El Hachem, Charlotte Sonigo, Julie Benard, Marion Presse, Christophe Sifer, Nathalie Sermondade, Michael Grynberg
In vitro maturation (IVM) of oocytes retrieved at germinal vesicle or Metaphase I stage, followed by vitrification of Metaphase II (MII) oocytes, has recently emerged as an option for urgent fertility preservation (FP). Priming is usually achieved with an injection of hCG, 10,000 IU, 36 hours before retrieval. This study aimed to assess a new method of priming, using GnRH agonists, and compare it to hCG, in cancer patients undergoing urgent FP. From 2009 to 2015, 373 cancer patients underwent MII oocyte cryopreservation after IVM cycles primed either with GnRHa (triptorelin 0...
2018: PloS One
Charlotte Steenblock, Maria F Rubin de Celis, Luis F Delgadillo Silva, Verena Pawolski, Ana Brennand, Martin Werdermann, Ilona Berger, Alice Santambrogio, Mirko Peitzsch, Cynthia L Andoniadou, Andrew V Schally, Stefan R Bornstein
The adrenal gland is a master regulator of the human body during response to stress. This organ shows constant replacement of senescent cells by newly differentiated cells. A high degree of plasticity is critical to sustain homeostasis under different physiological demands. This is achieved in part through proliferation and differentiation of adult adrenal progenitors. Here, we report the isolation and characterization of a Nestin+ population of adrenocortical progenitors located under the adrenal capsule and scattered throughout the cortex...
December 4, 2018: Proceedings of the National Academy of Sciences of the United States of America
Steven Lehrer, Peter H Rheinstein, Kenneth E Rosenzweig
Background: Two large studies suggest that risk is not increased. But other studies have found increased risk of Alzheimer's disease and impaired cognition. Objective: To determine whether androgen deprivation therapy increases the risk of impaired cognition or Alzheimer's disease in men with prostate cancer. Methods: We used data from MedWatch, the Food and Drug Administration (FDA) Safety Information and Adverse Event Reporting Program. Machine-readable data from MedWatch, including adverse drug reaction reports from manufacturers, are part of a public database...
June 30, 2018: JAD Reports
Raphael Ouede, Blaise Demine Alexandre, Ayegnon Kouakou Gregoire, Landry Kohou-Kone, Edouard N'guessan, Maurice Gabin Kouacou, Jean-Marcel Ahui Brou, Flavien Kouassi Kendja, Yves Tanauh
This study aims to propose a therapeutic approach for catamenial pneumothorax based on outcomes reported in 18 cases. We conducted a retrospective study of 18 female elderly patients with an average age of 32.2 years who had undergone surgery for right (16 cases) and bilateral catamenial pneumothorax (2 cases) from January 1994 to December 2016. The patients were divided into 3 groups on the basis of the evolution of our surgical capability over time: group 1(G1) from January 1994 to June 2006, group 2 (G2) from July 2006 to February 2008, group 3(G3) from March 2008 to December 2016, these groups were composed of 5, 2 and 11 patients respectively...
2018: Pan African Medical Journal
N K Akhkubekova, A S Kaysinova, A A Fedorov, N B Efimenko, I I Gaidamaka, E N Chalaja, L A Cherevashchenko, L V Tsallagova, E E Urvacheva, A B Ovsienko
BACKGROUND: The use of agonists of gonadotropin-releasing hormone (GnRH) for the rehabilitation treatment of the patients presenting with endometriosis genitalis externa is known to significantly enhance the risk of development of hypoestrogenism. The so-called 'add-back-therapy' is carried out as a preventive measure to eliminate hypoestrogenism caused by the intake of GnRH agonists without detriment to the effectiveness of anti-hormonal therapy. AIM: The objective of the present study was to estimate the effectiveness of the new method ('add-back hormone replacement therapy') in comparison with anti-hormonal therapy with the use of GRH agonists at the stage of the early postoperative medical rehabilitation based on the drinking of mineral waters (MW) and radon therapy (RT) in the patients who had undergone the laparoscopic interventions for the treatment of endometrioid heterotopies of the ovaries (1-3 months post-operatively)...
2018: Voprosy Kurortologii, Fizioterapii, i Lechebnoĭ Fizicheskoĭ Kultury
Shuhui Zheng, Hang Zhou, Bo Gao, Yongyong Li, Zhiheng Liao, Taifeng Zhou, Chengjie Lian, Zizhao Wu, Deying Su, Tingting Wang, Peiqiang Su, Caixia Xu
This study aimed to verify the effects of estrogen on the onset and development of adolescent idiopathic scoliosis and the mechanisms associated with these effects by constructing a pubescent bipedal rat model. Experiments were conducted to investigate whether scoliosis progression was prevented by a Triptorelin treatment. One hundred twenty bipedal rats were divided into female, OVX (ovariectomy), OVX + E2, Triptorelin, sham, and male groups. According to a spinal radiographic analysis, the scoliosis rates and curve severity of the female and OVX + E2 groups were higher than those in the OVX, Triptorelin, and male groups...
November 7, 2018: Experimental & Molecular Medicine
Jingjing Jiang, Shanshan Gao, Jin Xu
BACKGROUND The aim of this study was to compare the efficacy and safety of 2 GnRH agonists - triptorelin acetate and cetrorelix acetate - in assisted reproduction. MATERIAL AND METHODS A total of 182 females who received in vitro fertilization and embryo transfer (IVF+ET) from March 2014 to July 2014 were involved, and their clinical data were retrospectively analyzed. Among them, 91 patients received treatment with short-acting triptorelin (group A) and another 91 patients were treated with cetrorelix acetate (group B)...
November 8, 2018: Medical Science Monitor: International Medical Journal of Experimental and Clinical Research
Peter B Østergren, Caroline Kistorp, Mikkel Fode, Finn N Bennedbaek, Jens Faber, Jens Sønksen
OBJECTIVES: To compare the metabolic changes between men with advanced prostate cancer commenced on a gonadotropin-releasing hormone (GnRH) agonist and those treated with orchiectomy. PATIENTS AND METHODS: Fifty-eight hormone-naive men with advanced prostate cancer were randomly assigned (1:1) to either subcapsular orchiectomy or triptorelin 22.5 mg/24week depot injections. The participants were followed for 48 weeks, with study visits at baseline, 12, 24 and 48 weeks...
November 2, 2018: BJU International
Huiling Xue, Meiyun Liu, Wanjiao Hao, Ye Li
Objective: To investigate the effects of laparoscopic surgery combined with triptorelin acetate, gestrinone and mifepristone on pregnancy rate, pregnancy outcome, long-term recurrence and adverse reactions in patients with endometriosis (EMT) complicated with infertility. Methods: In this study, 150 patients with EMT and infertility were selected and randomly divided into triptorelin group (group A), gestrinone group (group B) and mifepristone group (group C), with 50 people in each group...
September 2018: Pakistan Journal of Medical Sciences Quarterly
Hsin-Yi Cheng, Hsin-Yang Li
OBJECTIVE: To report the management and prevention of pre-operative ovulation before oocyte retrieval with emergent administration of indomethacin. CASE REPORT: During in vitro fertilization (IVF) treatment, the patient described here mistakenly administered 6500 IU of hCG and 0.2 mg of triptorelin (GnRHa) 9 h earlier than scheduled triggering. To avoid emergent oocyte retrieval in the midnight, indomethacin was given (150 mg/day, there times a day) from 2 h after incorrect hCG and GnRHa injection to the night before ovum pickup...
October 2018: Taiwanese Journal of Obstetrics & Gynecology
Yaping Ma, Shuang Nie, Ze Ben, Zhuangjian Xu, Huan Zhou, Jinling Zhao, Feng Ren, Qing Wang, Shuyan Xie, Tingting Zhang
BACKGROUND: Gonadotropin-releasing hormone stimulation test is a gold standard for evaluating the function of the hypothalamic-pituitary-gonadal axis (HPGA) in children. These tests are usually uncomfortable because of multi-venipunctures. A urine specimen is a good alternative because it is noninvasive and convenient. More studies have shown the correlation between sera and urine LH and FSH levels under different physiological and pathological conditions. METHODS: The study investigated the dynamic trends of urine LH (uLH) and FSH (uFSH) assayed by immunochemiluminometric assays (ICMA) during triptorelin stimulation tests in girls...
October 1, 2018: Clinical Laboratory
I A Franzini, F M Yamamoto, F Bolfi, S R Antonini, V S Nunes-Nogueira
Objective We assessed the effectiveness of puberty blockade with a gonadotropin-releasing hormone (GnRH) analog in increasing adult height (AH) in girls with puberty onset between 7 and 10 years of age. Methods We performed a systematic review and included controlled studies in which girls with early puberty (EP) were assigned to the GnRH analog or no treatment groups. The primary outcome analyzed was AH. Search strategies were applied to the MEDLINE, EMBASE, LILACS and CENTRAL databases. Results We identified 1514 references, and six studies fulfilled our eligibility criteria...
December 1, 2018: European Journal of Endocrinology
Antonio Aliberti, Maida Bada, Sebastiano Rapisarda, Clara Natoli, Luigi Schips, Luca Cindolo
BACKGROUND: Androgen-deprivation therapy is one of the options available for treating both advanced and metastatic prostate cancer (PCa). It is used as an adjuvant or neoadjuvant therapy, either alone or in combination with radiotherapy (RT) or surgery. The aim of this study is to appraise adherence to ADT. METHODS: A total of 136 PCa patients on ADT (leuprorelin, triptorelin, and degarelix) were monitored between January 2008 and December 2015. Demographic, histopathological, and clinical data were collected...
September 19, 2018: Minerva Urologica e Nefrologica, the Italian Journal of Urology and Nephrology
Masoumeh Zoghi, Sima Attar Nosrati, Faramarz Rogni, Saaed Rajabifar
The new GnRH-Ιanalogue developed in this paper was based on the D-Trp6 -GnRH-Ι-scaffold, and its potency was increased by the replacement Gly-NH2 by NH-NH2 binding to the Gly at position 10. Triptorelin-Hydrazide analogue was synthesized using solid phase. For 111 In labeling, synthesized peptide was followed by conjugation with DOTA using pSCN-Bn-DOTA. The conjugated Triptorelin-Hydrazide was labeled with 500-550 MBq of 111 In-chloride (in 0.2 M HCl). At optimized conditions after labeling, radio-chromatography showed radiochemical purity of approximately equal to 98% (RTLC) and greater than 95% (HPLC)...
August 14, 2018: Journal of Labelled Compounds & Radiopharmaceuticals
Laura Palma, Rossella Gaudino, Paolo Cavarzere, Franco Antoniazzi
BACKGROUND: Gonadotropin-releasing hormone agonists (GnRH-a) are common treatment options for central precocious puberty (CPP) in childhood. GnRH-a treatment is useful and has a good safety profile, with minimal adverse effects and no severe long-term consequences. The common side effects in children are menopause-like symptoms and local adverse events at the injection site. CASE PRESENTATION: We present the case of a girl with CPP who developed arterial hypertension from treatment with GnRH-a (triptorelin)...
August 8, 2018: Journal of Pediatric Endocrinology & Metabolism: JPEM
Ronit Beck-Fruchter, Shira Baram, Yoel Geslevich, Amir Weiss
BACKGROUND/AIMS: Gonadotropin releasing hormone (GnRH) agonist triggering results in an endogenous gonadotropin flare. Although it effectively stimulates ovulation, GnRH agonist triggers results in an early luteolysis and requires modification of the luteal support. The current study aims to evaluate GnRH agonist triggering with exclusive human chorionic gonadotropin (hCG) luteal support. METHODS: In this prospective observational study, 56 normogonadotropic-assisted reproductive technology patients, stimulated using a GnRH-antagonist protocol, were studied...
July 26, 2018: Gynecologic and Obstetric Investigation
Silvano Bertelloni, Cristina Mucaria, Giampiero I Baroncelli, Diego Peroni
Triptorelin depot is largely used to treat central precocious puberty (CPP) in children. Areas covered: This review updates triptorelin depot treatment of CPP, focusing on trials that compared 3.75 mg/28 day treated and untreated children till the adult height (AH). Efficacy of the new 11.25 mg/90 days or 22.5 mg/6 month formulations in suppressing pituitary-gonadal axis in short-term trials is also addressed. Short- and long-term safety was summarized. Expert commentary: Long experience on triptorelin depot use in children with CPP is available...
July 2018: Expert Review of Clinical Pharmacology
Francis de Zegher, Nele Reynaert, Lien De Somer, Carine Wouters, Mathieu Roelants
BACKGROUND: Biologicals targeting the interleukin (IL)-1β or IL-6 pathway are becoming prime choices for the treatment of children with systemic juvenile idiopathic arthritis (sJIA). Up to 1 in 3 sJIA children receiving such treatment continues to have inflammatory activity and to require supra-physiological glucocorticoid doses which may reduce growth velocity for years and may lead to an extremely short stature for age, if not for life. Currently, there is no long-term proposal to normalize the adult height of these children with sJIA...
June 25, 2018: Hormone Research in Pædiatrics
K Hachi, K Boualga, K Chettibi, M Harouni, M Ounnoughene, N Bekkat-Berkani, P Maisonobe, M J Yousfi
INTRODUCTION: This study aims to assess the effectiveness of triptorelin on lower urinary tract symptoms (LUTS) in Algerian patients with non-localized prostate cancer in routine practice. MATERIALS: This prospective, observational, non-interventional, multicentre study was conducted in Algeria. Included patients who had locally advanced or metastatic prostate cancer and were treated with triptorelin 11.25mg given every 12 weeks. LUTS were evaluated with the International Prostate Symptom Score (IPSS) until week 48 after treatment initiation...
June 2018: Progrès en Urologie
Sabine Schuster, Beáta Biri-Kovács, Bálint Szeder, Viktor Farkas, László Buday, Zsuzsanna Szabó, Gábor Halmos, Gábor Mező
Gonadotropin releasing hormone-III (GnRH-III), a native isoform of the human GnRH isolated from sea lamprey, specifically binds to GnRH receptors on cancer cells enabling its application as targeting moieties for anticancer drugs. Recently, we reported on the identification of a novel daunorubicin-GnRH-III conjugate (GnRH-III-[4 Lys(Bu), 8 Lys(Dau=Aoa)] with efficient in vitro and in vivo antitumor activity. To get a deeper insight into the mechanism of action of our lead compound, the cellular uptake was followed by confocal laser scanning microscopy...
2018: Beilstein Journal of Organic Chemistry
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"